Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

FACCT Trial
 
NCT04392973
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
125/129 inconclusive
  • inconclusive 15 % decrease in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine
 
NCT04322123
RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
221/227 safety concern
  • statistically significant 74 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
7 studies excluded by filtering options (6 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).